June 4, 2019 / 3:48 PM / 15 days ago

BRIEF-Abbvie Presents Data From Venetoclax Chemotherapy-Free Combination Regimen For Patients With Previously Untreated Chronic Lymphocytic Leukemia

June 4 (Reuters) - AbbVie Inc:

* ABBVIE PRESENTS DATA FROM VENETOCLAX CHEMOTHERAPY-FREE COMBINATION REGIMEN FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA

* ABBVIE INC - PATIENTS TREATED WITH VENETOCLAX PLUS OBINUTUZUMAB LIVED SIGNIFICANTLY LONGER WITHOUT THEIR DISEASE PROGRESSING

* ABBVIE INC - RATES OF MINIMAL RESIDUAL DISEASE NEGATIVITY IN PERIPHERAL BLOOD WERE HIGHER IN PATIENTS TREATED WITH VENETOCLAX PLUS OBINUTUZUMAB

* ABBVIE INC - IN CLL14 TRIAL, ADVERSE EVENTS (AES) WERE CONSISTENT WITH KNOWN SAFETY PROFILES OF VENETOCLAX AND OBINUTUZUMAB ALONE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below